Fewer injections may be needed with triamcinolone therapy for DME

Fewer injections were needed in patients with diabetic macular edema when either triamcinolone monotherapy or combined bevacizumab-triamcinolone therapy was used compared with bevacizumab alone, according to a study. Researchers evaluated the efficacy of Avastin (bevacizumab, Genentech) and triamcinolone (Ophthalmos Pharmaceutical Industry) in combination and alone in 111 patients with DME from eight clinical sites in Brazil. The primary outcome was visual acuity at 6 months.